For more than 30 years, topical minoxidil has been the only FDA-approved treatment for female pattern hair loss. Veradermics is now developing VDPHL01, an extended-release oral minoxidil tablet designed specifically for pattern hair loss.
Early Phase 2 results are promising, but the medication remains investigational and is not yet FDA approved.
Why Is a New Treatment Needed?
Female pattern hair loss affects approximately 30 million women in the United States. Although topical minoxidil can be effective, daily scalp application may be inconvenient, irritating, or cosmetically unappealing.
Dermatologists may also recommend off-label oral medications, supplements, low-level light therapy, platelet-rich plasma, or hair transplantation. However, these options vary in effectiveness, cost, accessibility, and potential risks.
What Is VDPHL01?
VDPHL01 contains oral minoxidil in an extended-release tablet. Its gel-matrix delivery system is designed to maintain steadier medication levels and reduce the sharp concentration peaks associated with immediate-release oral minoxidil.
In theory, this could support hair growth while potentially reducing cardiovascular side effects. Larger studies are needed to confirm these benefits.
What Did the Phase 2 Study Find?
The Phase 2 study included 28 women with mild-to-moderate female pattern hair loss who took VDPHL01 once or twice daily.
After six months, participants experienced an average increase of approximately 23 hairs per square centimeter. Some reportedly noticed improvement after about two months, and no serious adverse events were reported.
However, the study was small. These findings must be confirmed in larger randomized trials before firm conclusions can be made about effectiveness and long-term safety.
What Happens Next?
Veradermics is conducting a larger Phase 2/3 study involving more than 500 women. The trial will evaluate:
- Hair density and treatment durability
- Side effects and cardiovascular safety
- Differences between dosing schedules
Initial results are expected during the first half of 2027.
Could It Become the First Approved Oral Option?
Oral minoxidil is already prescribed off label by some dermatologists. However, an FDA-approved formulation studied specifically for hair loss could provide clearer guidance on dosing, effectiveness, and safety monitoring.
The Bottom Line
VDPHL01 is an extended-release oral minoxidil treatment being studied for female pattern hair loss. Early results showed increased hair density with no serious adverse events in a small Phase 2 study.
The findings are encouraging, but VDPHL01 is not yet FDA approved or available by prescription. Larger clinical trials are still needed to determine whether it is safe and effective for long-term use.
References
- Bosslett M. “Veradermics Launches Phase 2/3 Trial for VDPHL01, a Potential First FDA-Approved Oral Treatment for FPHL.” Dermatology Times.
Leave A Comment